Core Points - Inbank has approved its Financial Calendar for the 2026 financial year, detailing key dates for financial disclosures and the Annual General Meeting [1] - The company is a financial technology firm with an EU banking license, facilitating connections among merchants, consumers, and financial institutions through its embedded finance platform [1] - Inbank has established partnerships with over 5,900 merchants and maintains more than 915,000 active contracts, collecting deposits across seven European markets [1] - The company's bonds are listed on the Nasdaq Tallinn Stock Exchange [1] Financial Disclosure Dates - February 26, 2026: Q4 and 2025 Full Year Unaudited Interim Report [1] - March 5, 2026: 2025 Audited Annual Report [1] - March 31, 2026: Annual General Meeting [1] - April 30, 2026: Q1 Interim Report [1] - July 30, 2026: Q2 Interim Report [1] - October 29, 2026: Q3 Interim Report [1]

Core Insights - Tryg will conduct pre-close analyst calls starting on 17 December 2025, ahead of Q4 2025 results release on 22 January 2026 [1] Insurance Revenue Growth - Tryg's insurance revenue is distributed as follows: approximately 50% from Denmark, 30% from Sweden, and 20% from Norway, with Q4 2024 insurance revenue reported at DKK 9,734 million [2] Revenue Development - In Q3 2025, Tryg reported a growth of 4.0% in local currencies, adjusted for a one-off positive impact of approximately DKK 50 million from Q3 2024 [3] Claims Environment - The underlying claims ratio for Tryg was 69.3% in Q4 2024, with expectations for stable to slightly improving performance towards 2027 [4] Weather and Large Claims - Normalized weather claims for Q4 are expected to be DKK 240 million, which is 30% of the annual guidance of DKK 800 million [5] Interest Rates Development - The expected discount rate for Q4 is approximately 2.4%, consistent with Q3 2025 [6] Run-off Expectations - Tryg anticipates a long-term run-off expectation of approximately 2% towards 2027 [7] Investment Activities - Tryg's investment activities include a match portfolio of approximately DKK 45 billion and a free portfolio of approximately DKK 14 billion as of Q3 2025 [8] Other Income and Costs - Other income and costs are guided between DKK -350 million and DKK -370 million quarterly, primarily due to amortization of intangibles from the RSA Scandinavia acquisition [10] Solvency - On 11 November 2025, Tryg issued a new Restricted Tier 1 capital instrument of SEK 1 billion, positively impacting the solvency position by approximately SEK 300 million [11] Number of Shares - As of the end of Q3 2025, Tryg reported 602,428,000 outstanding shares, with no material changes expected [13] Outlook Statement - Tryg targets its highest ever insurance service result of DKK 8.0-8.4 billion by 2027, following an insurance service result of around DKK 7.2 billion in 2024 [14]

Core Insights - Safe has signed an exclusive distribution agreement with Vortrom Biologics for the Spanish market, aiming to accelerate its development in Spain [1][2][4]. Group 1: Strategic Partnership - Vortrom, a major distributor of medical equipment in Spain for over 40 years, is now the exclusive partner for Safe Group's surgical solutions [2][3]. - This partnership is part of Safe's strategy to enhance its international expansion and strengthen its presence in key European markets [2][4]. Group 2: Market Opportunity - Spain, with a population of over 47 million and a modern healthcare system, presents significant growth potential for Safe [4]. - The collaboration with Vortrom will leverage its commercial strength and credibility to effectively penetrate the Spanish market [4]. Group 3: Leadership Statements - Philippe Laurito, CEO of Safe Group, expressed pride in partnering with Vortrom, highlighting the appeal of Safe's innovative solutions and the strategic nature of the partnership [5]. - Lucía Muñoz, CEO of Vortrom Biologics, emphasized the alignment of Safe's technologies with the needs of Spanish surgeons and their strategy to offer advanced solutions [5]. Group 4: Company Overview - Safe Group is a French medical technology company that includes Safe Orthopaedics and Safe Medical, employing approximately 100 people [6]. - Safe Orthopaedics specializes in ready-to-use technologies for spine pathologies, while Safe Medical focuses on implantable medical devices and offers various industrial services [7].

Core Points - Sampo plc has initiated a share buyback program with a maximum limit of EUR 150 million, which commenced on 6 November 2025 [1][2] - On 16 December 2025, Sampo plc acquired a total of 259,877 A shares at an average price of EUR 10.05 per share [1] - Following these transactions, Sampo plc now holds a total of 7,173,489 A shares, representing 0.27% of the total shares outstanding [2] Summary by Category Share Buyback Program - The share buyback program was announced on 5 November 2025 and is in compliance with the Market Abuse Regulation [1] - The program is based on the authorization granted by Sampo's Annual General Meeting on 23 April 2025 [1] Transaction Details - The breakdown of shares acquired on 16 December 2025 includes: - 11,821 shares on AQEU at EUR 10.05 - 98,289 shares on CEUX at EUR 10.05 - 37,825 shares on TQEX at EUR 10.05 - 111,942 shares on XHEL at EUR 10.05 [1] Current Holdings - After the buybacks, Sampo plc's total holdings of A shares amount to 7,173,489, which is 0.27% of the total shares [2]

Core Insights - Sanofi has made its Q4 2025 Aide memoire available on its website to assist in financial modeling of the Group's quarterly results [1] - The document includes reminders on non-comparable items, foreign currency impact, and share count [1] - Sanofi's Q4 and full year 2025 results are scheduled for publication on January 29, 2026 [1] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and delivering growth [2] - The company leverages its understanding of the immune system to develop medicines and vaccines for millions globally [2] - Sanofi aims to address urgent healthcare, environmental, and societal challenges through its innovative pipeline [2] Stock Information - Sanofi is listed on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY [3]

Core Insights - Exosens has been awarded the EcoVadis Gold Medal, recognizing its commitment to corporate social responsibility (CSR) and placing it among the top 5% of assessed organizations [1][8] - The company achieved a score of 82/100, indicating its leadership within the Aerospace & Defense sector in terms of CSR practices [8] Group CSR Framework - The EcoVadis assessment highlights the robust structuring of Exosens' CSR approach across key pillars, including environmental performance, social and human rights, ethics, and responsible purchasing [2][8] - Environmental initiatives include annual carbon footprint calculations and tailored action plans aimed at reducing environmental impacts [2] Social and Human Rights - Exosens has established a consistent HR framework that ensures safe and equitable working conditions, supported by skills development programs and structured social dialogue [3] Ethics and Compliance - The evaluation recognizes Exosens' comprehensive program for ethics and compliance, which includes anti-corruption measures, conflict-of-interest management, and whistleblowing systems [4] Responsible Procurement - Progress in responsible procurement is acknowledged, driven by a formalized policy and the integration of ESG criteria within purchasing processes [5] Company Commitment - The CFO of Exosens emphasized that the Gold Medal reflects the continuous efforts to reinforce CSR commitments and the engagement of teams in embedding sustainability into practices [6] Company Overview - Exosens is a high-tech company with over 85 years of experience in electro-optical technologies, employing more than 2000 people across 12 sites in Europe and North America [7] - The company is listed on Euronext Paris and is recognized as a major innovator in optoelectronics [7]

Core Insights - Nyxoah has announced the commercial launch of its Genio® system in the Netherlands, with successful implants performed at OLVG West and Zuyderland hospitals [1][2] - The Genio system is designed as a breakthrough therapy for Obstructive Sleep Apnea (OSA), providing an alternative for patients who cannot tolerate CPAP [2][3] - The launch reflects Nyxoah's ongoing expansion in Europe and the growing adoption of its bilateral, externally powered Genio therapy [2] Company Overview - Nyxoah is a medical technology company focused on innovative solutions for treating OSA, with its lead product being the Genio system, which is leadless and battery-free [3] - The company aims to improve the quality of life for OSA patients, who face increased mortality risk and cardiovascular issues [3] Product Features - The Genio system stimulates both branches of the nerve, is MRI-compatible, and can be upgraded via an external activation chip, making it a promising long-term solution [2] - The absence of an implanted battery and reliable performance in the supine position are highlighted as significant advantages of the Genio system [2] Regulatory Milestones - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4] - Nyxoah has also completed IPOs on Euronext Brussels and NASDAQ, and received FDA approval for a subset of adult patients with moderate to severe OSA in August 2025 [4]

Core Insights - The European Medicines Agency (EMA) has granted orphan designation to efdoralprin alfa for the treatment of alpha-1 antitrypsin deficiency (AATD) related emphysema, addressing a significant unmet medical need in a rare respiratory condition [1][2][3] Group 1: Efdoralprin Alfa Overview - Efdoralprin alfa (SAR447537, formerly INBRX-101) is an investigational recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein aimed at treating AATD emphysema [1][4] - The drug has shown superiority over standard plasma-derived therapy in adults with AATD in the global phase 2 ElevAATe study, meeting all primary and key secondary endpoints [2][4] - Efdoralprin alfa has also received fast track and orphan drug designations from the US FDA, indicating its potential significance in treating AATD [3][4] Group 2: Alpha-1 Antitrypsin Deficiency (AATD) - AATD is a rare inherited disorder characterized by low or absent levels of AAT, leading to progressive lung and liver tissue damage [5] - Approximately 235,000 individuals globally are affected by AATD, with nearly 100,000 in the US, and about 90% of these cases remain undiagnosed [5] Group 3: Sanofi's Commitment - Sanofi is dedicated to developing treatments for rare diseases, as evidenced by the recent orphan designation for efdoralprin alfa [7] - The company emphasizes its commitment to improving lives through innovative research and development in the biopharma sector [6]

Core Points - FLSmidth & Co. A/S holds a total of 2,895,790 treasury shares, which represents approximately 5.02% of the Company's total share capital and voting rights, exceeding the 5% threshold [1] Company Overview - FLSmidth is a full flowsheet technology and service supplier to the global mining industry, focusing on improving performance, lowering operating costs, and reducing environmental impact [2] - The company's sustainability ambition, MissionZero, aims for zero emissions in mining by 2030, with a commitment to improving sustainability performance and becoming carbon neutral in its own operations by 2030 [2]

Core Insights - Synaptics Incorporated is set to showcase its AI-native processing, sensing, and connectivity technologies at CES 2026, highlighting the transformation of real-world applications across various markets [1][2][7] Group 1: Product Innovations - The Astra AI-native SoCs enable local processing of voice, gesture, and motion, enhancing responsiveness and privacy while minimizing cloud reliance [3] - Veros wireless solutions provide long-range, low-latency connectivity, extending the capabilities of smart devices [3] - The multimodal sensing portfolio includes touch, biometric, vision, and display innovations, creating personalized and immersive user experiences across multiple device categories [5] Group 2: Application Areas - In smart home automation, Synaptics' technologies facilitate context-aware automation, improving user interaction and device efficiency [3] - For robotics and industrial automation, the integration of Astra processors and Veros connectivity supports real-time intelligence, predictive maintenance, and operational efficiency [4] - Personal devices and computing benefit from enhanced human interaction through advanced sensing technologies, making devices more intuitive and secure [5] Group 3: Event Participation - Synaptics will host immersive technology demonstrations at CES 2026, allowing visitors to experience the full range of Edge AI, wireless, audio, touch, biometrics, and automotive solutions [6]